2,435 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Machina Capital S.A.S.

Machina Capital S.A.S. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,435 shares of the medical research company’s stock, valued at approximately $715,000.

Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. raised its position in Thermo Fisher Scientific by 4.1% in the 1st quarter. BlackRock Inc. now owns 27,251,678 shares of the medical research company’s stock valued at $7,459,327,000 after purchasing an additional 1,074,400 shares during the last quarter. FMR LLC increased its stake in shares of Thermo Fisher Scientific by 33.5% in the 1st quarter. FMR LLC now owns 11,572,581 shares of the medical research company’s stock valued at $3,167,647,000 after buying an additional 2,900,868 shares during the period. Geode Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 4,897,714 shares of the medical research company’s stock valued at $1,094,013,000 after buying an additional 422,625 shares during the period. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $946,280,000. Finally, Clearbridge Investments LLC increased its stake in shares of Thermo Fisher Scientific by 2.4% in the 1st quarter. Clearbridge Investments LLC now owns 3,089,195 shares of the medical research company’s stock valued at $845,574,000 after buying an additional 71,898 shares during the period. Institutional investors and hedge funds own 87.97% of the company’s stock.

Several equities research analysts have recently commented on TMO shares. BTIG Research lifted their target price on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a research note on Thursday, May 23rd. UBS Group cut AGL Energy to a “sell” rating in a research note on Thursday, May 23rd. Zacks Investment Research raised Eutelsat Communications from a “hold” rating to a “strong-buy” rating and set a $21.00 target price for the company in a research note on Wednesday, June 12th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $302.55.

In other news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the sale, the chief financial officer now directly owns 40,029 shares in the company, valued at $10,739,380.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director C Martin Harris sold 275 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now owns 6,433 shares in the company, valued at $1,741,606.09. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by insiders.

Shares of Thermo Fisher Scientific stock traded down $1.55 during trading on Wednesday, reaching $282.36. 20,088 shares of the company were exchanged, compared to its average volume of 1,274,024. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The business’s 50-day simple moving average is $291.77. The stock has a market cap of $114.88 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 1.88 and a beta of 1.10.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. During the same period in the previous year, the firm earned $2.75 earnings per share. The company’s revenue was up 3.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 12.23 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be paid a $0.19 dividend. The ex-dividend date of this dividend is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 6.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.